Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoflurane and sevoflurane are halogenated inhalational anesthetics used for induction and maintenance of general anesthesia. Both affect the nicotinic acetylcholine receptor through similar mechanisms, influencing the open and closed states of the channels. Sevoflurane has a faster onset and often quicker recovery time compared to isoflurane due to its lower blood-gas solubility. Both drugs enhance inhibitory postsynaptic channel activity by binding to GABA-A and glycine receptors, while inhibiting excitatory synaptic channel activity by binding to nicotinic acetylcholine, serotonin, and glutamate receptors. They are commonly used in both human and veterinary medicine, with sevoflurane increasingly replacing isoflurane in modern anesthesia practice, particularly for outpatient procedures and pediatric anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoflurane + sevoflurane.